Search Result

Results for "

IL-2 secretion

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Interleukin Related (31) Itk (1) Adenosine Receptor (1) Akt (3) Apoptosis (4) Autophagy (2) Calcium Channel (2) Caspase (2) CTLA-4 (2) Cytochrome P450 (1) DGK (2) DNA/RNA Synthesis (2) Drug Derivative (1) E1/E2/E3 Enzyme (3) Ferroptosis (2) Fungal (2) HBV (2) HIF/HIF Prolyl-Hydroxylase (2) IFNAR (8) LAG-3 (1) MALT1 (1) MAP4K (8) NF-κB (1) NOD-like Receptor (NLR) (2) PD-1/PD-L1 (4) PI3K (3) Potassium Channel (4) PROTACs (2) Reference Standards (5) SOD (2) Tim3 (1) TNF Receptor (4) Toll-like Receptor (TLR) (1) VISTA (1)
By Research Areas:	Cancer (30) Cardiovascular Disease (6) Infection (2) Inflammation/Immunology (26) Metabolic Disease (2) Neurological Disease (1)

By Targets:

Interleukin Related (31)

Itk (1)

Adenosine Receptor (1)

Akt (3)

Apoptosis (4)

Autophagy (2)

Calcium Channel (2)

Caspase (2)

CTLA-4 (2)

Cytochrome P450 (1)

DGK (2)

DNA/RNA Synthesis (2)

Drug Derivative (1)

E1/E2/E3 Enzyme (3)

Ferroptosis (2)

Fungal (2)

HBV (2)

HIF/HIF Prolyl-Hydroxylase (2)

IFNAR (8)

LAG-3 (1)

MALT1 (1)

MAP4K (8)

NF-κB (1)

NOD-like Receptor (NLR) (2)

PD-1/PD-L1 (4)

PI3K (3)

Potassium Channel (4)

PROTACs (2)

Reference Standards (5)

SOD (2)

Tim3 (1)

TNF Receptor (4)

Toll-like Receptor (TLR) (1)

VISTA (1)

By Research Areas:

Cancer (30)

Cardiovascular Disease (6)

Infection (2)

Inflammation/Immunology (26)

Metabolic Disease (2)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: Itk Interleukin Related IRAK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99156

Relatlimab 3 Publications Verification BMS-986016	LAG-3	Cancer
Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC₅₀ value of 0.67 nM and LAG-3/FGL1 interaction with an IC₅₀ value of 0.019 nM. Relatlimab can be used in research of cancer .

HY-113494

Sitostanol 1 Publications Verification Stigmastanol; 24α-Ethyl cholestanol	Interleukin Related	Others Metabolic Disease Inflammation/Immunology Cancer
Stigmastanol is a 6-amino derivative. Stigmastanol can be isolated from Hypericum riparium. Stigmastanol increases the secretion of *IL-2* and IL-10. Stigmastanol reduces the maximum mitochondrial respiration of cells. Stigmastanol has beneficial effects on the weakened immune function of asthma .

HY-136339

Cbl-b-IN-1 1 Publications Verification	E1/E2/E3 Enzyme Interleukin Related	Inflammation/Immunology Cancer
Cbl-b-IN-1 (Example 519) is an inhibitor of Cbl-b, with an IC₅₀ of less than 100 nM. Cbl-b-IN-1 can promote the secretion of cytokines such as IL-2, IFN-γ, and TNF-α, facilitate T cell activation, and enhance the TCR signaling pathway. Cbl-b-IN-1 can be used in research on immunomodulation .

HY-N0534

Vitexin-2"-O-rhamnoside	DNA/RNA Synthesis Apoptosis PI3K Akt Caspase SOD Interleukin Related	Cardiovascular Disease Inflammation/Immunology Cancer
Vitexin-2"-O-rhamnoside is an orally active flavonoid glycoside. Vitexin-2"-O-rhamnoside inhibits Apoptosis, increases the phosphorylation levels of PI3K/Akt, inhibits caspase-3, SOD activity, and promotes cytokine (IL-2, IL-6, and IL-12) secretion. Vitexin-2"-O-rhamnoside strongly inhibits DNA synthesis in MCF-7 cells with an IC₅₀ of 17.5 μM. Vitexin-2"-O-rhamnoside enhances immune function and improves the absorption of active compounds. Vitexin-2"-O-rhamnoside has antioxidant activity. Vitexin-2"-O-rhamnoside is used in the study of cardiovascular disease and immune-related diseases .

HY-N6939

Pseudolaric Acid B 2 Publications Verification	HBV Fungal Apoptosis Autophagy Ferroptosis Interleukin Related HIF/HIF Prolyl-Hydroxylase	Infection Cardiovascular Disease Inflammation/Immunology Cancer
Pseudolaric Acid B is an orally active diterpene acid. Pseudolaric Acid B has anti-fungal, anti-fertility, anti-angiogenesis and anticancer activity, and can induce tumor cell apoptosis and autophagy. In addition, Pseudolaric Acid B can inhibit the secretion of hepatitis B virus (HBV) and has immunosuppressive effect, selectively inhibiting the proliferation of T lymphocytes and the production of *IL-2* .

HY-P99159

Ivuxolimab	Interleukin Related	Cancer
Ivuxolimab is a fully human IgG2 agonist targeting OX40 (CD134), which selectively binds to the OX40 receptor on the surface of activated CD4 ⁺ and CD8 ⁺ T cells without inducing antibody-dependent cytotoxicity. Ivuxolimab can promote T cell proliferation, survival and cytokine (such as IFN-γ, *IL-2) secretion*, inhibit regulatory T cell function, and enhance anti-tumor immune response. Ivuxolimab can be used in the study of melanoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, etc .

HY-P99943

Erfonrilimab KN-046	PD-1/PD-L1 CTLA-4	Cancer
Erfonrilimab (KN-046) is a monoclonal antibody targeting PD-L1/CTLA-4. Erfonrilimab blocks the PD-L1 and CTLA-4 pathways, thereby regulating T cell function. Erfonrilimab enhances the secretion of *IL-2* in superantigen-stimulated peripheral blood mononuclear cells. Erfonrilimab inhibits tumor growth in xenograft and double gene knock-in mouse models. Erfonrilimab can be used in research related to a variety of advanced solid tumors, including non-small cell lung cancer and nasopharyngeal carcinoma.

HY-N0600

Ginsenoside F3	Interleukin Related IFNAR NF-κB	Inflammation/Immunology
Ginsenoside F3 is a saponin extracted from the leaves of Panax ginseng with immunoenhancing and antitumor immunostimulatory activities. Ginsenoside F3 upregulates RIPOR2 with a K_d value of 3.77 μM. Ginsenoside F3 enhances NF‑κB activation, upregulates T‑bet and downregulates GATA‑3, increases the production of *IL‑2* and IFN‑γ, decreases the production of IL‑4 and IL‑10, reverses CD8⁺ T‑cell exhaustion, restores cytokine secretion, and enhances antitumor immunity in a mouse non‑small cell lung cancer model. Ginsenoside F3 can be used for the research of non-small cell lung cancer .

HY-100712

DPO-1 1 Publications Verification	Potassium Channel Calcium Channel NOD-like Receptor (NLR) Interleukin Related	Cardiovascular Disease Inflammation/Immunology
DPO-1 is a potent Kv1.5 and Kv1.3 (EC₅₀ = 3.1 μM) channels inhibitor with potential immunomodulatory and anti-inflammatory effects. DPO-1 reduces Kv1.3 current density, blunts Ca ²⁺ influx in Ca ²⁺-depleted Jurkat cells, and inhibits *IL-2* secretion in activated Jurkat cells. DPO-1 inhibits Uric acid sodium (HY-B2130A) (MSU)-induced NLRP3 inflammasome activation by blocking Kv1.5-mediated K ⁺ efflux. DPO-1 can be used for the study of immunologic disorders and atrial fibrillation .

HY-134820

MLT-943	MALT1	Inflammation/Immunology
MLT-943 is a potent, selective and orally active MALT1 protease inhibitor. MLT-943 inhibits stimulated-IL-2 secretion in PBMC or in whole blood with a similar IC₅₀ across species (0.07-0.09 μM in PBMC, 0.6-0.8 μM in whole blood). MLT-943 has anti-inflammatory activities and can be used for FcgR-mediated inflammation research .

HY-173006

AZ3246	MAP4K Interleukin Related	Cancer
AZ3246 is an orally active and selective inhibitor of HPK1 with an IC₅₀ of < 3 nM. AZ3246 induces IL-2 secretion in T cells with an EC₅₀ of 90 nM. AZ3246 is a low-clearance antitumor compound that can be used for the study of breast cancer .

HY-13743

Roquinimex Linomide; FCF89; ABR212616	TNF Receptor Interleukin Related IFNAR	Neurological Disease Inflammation/Immunology Cancer
Roquinimex (Linomide) is an orally active immunomodulator with antineoplastic, anti-inflammatory, and antiangiogenic activity. Roquinimex suppresses TH1 lymphocyte cytokines (IL-2, IFN-γ), promotes TH2 lymphocyte cytokines (IL-4, IL-10), increases NK cell, activated monocyte, and T cell activity. Roquinimex blocks macrophage TNF-α production and suppresses IL-1/IL-6 secretion. Roquinimex exhibits in vivo antitumour activity, suppresses rodent autoimmune disease signs, and ameliorates murine colitis and psoriasis. Roquinimex can be used for the research of leukemia, inflammatory bowel disease, multiple sclerosis, and psoriasis .

HY-149917

ITK degrader 1	PROTACs Itk	Cancer
ITK degrader 1 is a highly selective degrader of interleukin-2-inducible T-cell kinase (ITK; DC₅₀=3.6 nM in vivo in mice), with good plasma exposure levels. ITK degrader 1 induces rapid, and prolonged ITK degradation and suppresses IL-2 secretion (EC₅₀=35.2 nM, Jurkat cells) stimulated by anti-CD3 antibodyin vivo. ITK degrader 1 consists of target protein ligand (red part) ITK ligand 1 (HY-168387), PROTAC linker (black part) Piperidine-C2-piperazine-Boc (HY-168388) and E3 ubiquitinase ligand (blue part) Thalidomide 5-fluoride (HY-W087383). E3 ubiquitinase and PROTAC linker can form Thalidomide-piperidine-C2-piperazine-Boc (HY-168389) .

HY-157838

HMC-B17	MAP4K	Cancer
HMC-B17 is a selective, orally bioavailable HPK1 inhibitor (IC₅₀ = 1.39 nM) that potentiates anti-PD-L1 efficacy. HMC-B17 potently enhances the IL-2 secretion in Jurkat cells (EC₅₀ = 11.56 nM). HMC-B17 can be used for the research of cancer .

HY-123590

BC12-4	Interleukin Related	Inflammation/Immunology
BC12-4 is a potent *IL-2* secretion inhibitor with immunomodulatory activity .

HY-149232

HPK1-IN-35	MAP4K	Cancer
HPK1-IN-35 is a potent and selective HPK1 inhibitor with an IC₅₀ value of 3.5 nM. HPK1-IN-35 decreases the expression of p-SLP76 and promotes IL-2 secretion .

HY-169318

DGKζ-IN-7	DGK Interleukin Related	Inflammation/Immunology Cancer
DGKζ-IN-7 (compound 97) is an oral active DGKζ inhibitor with the IC₅₀ of 33.4 nM. DGKζ-IN-6 inhibits the secretion of IL-2 and can be used for study of cancer and autoimmune diseases .

HY-169317

DGKζ-IN-6	DGK Interleukin Related	Inflammation/Immunology Cancer
DGKζ-IN-6 (compound 40) is an oral active DGKζ inhibitor with the IC₅₀ of 45.5 nM. DGKζ-IN-6 inhibits the secretion of IL-2 and can be used for study of cancer and autoimmune diseases .

HY-153952

Immuno modulator-1	TNF Receptor Interleukin Related Potassium Channel	Inflammation/Immunology Cancer
Immuno modulator-1 (compound 22) inhibits TNFα and *IL-2* secretion in human peripheral blood mononuclear cells (hPBMC), with IC₅₀ values of 4.7 and 26 nM, respectively. Immuno modulator-1 shows hERG potassium channel blocking effect, with Inhibitory percentage of 20% at 3 μM .

HY-172875

HPK1-IN-58	MAP4K Interleukin Related	Inflammation/Immunology Cancer
HPK1-IN-58 (Compound 26) is an inhibitor of HPK1 (IC₅₀: 2.6 nM) and SLP76 (IC₅₀: 20 nM). HPK1-IN-58 enhances IL-2 secretion and reverses PGE2-induced immunosuppression. HPK1-IN-58 can be used in anti-tumor immunity research .

HY-173311

Cbl-b-IN-28	E1/E2/E3 Enzyme Interleukin Related	Inflammation/Immunology Cancer
Cbl-b-IN-28 (Compound B2) is an orally active Cbl-b inhibitor. Cbl-b-IN-28 promotes the secretion of cytokines such as *IL-2* and enhances the function of immune cells by regulating the phosphorylation levels of key proteins in the T-cell receptor signaling pathway. Cbl-b-IN-28 can be used in research in the field of cancer immunology .

HY-113494R

Sitostanol (Standard) Stigmastanol (Standard); 24α-Ethyl cholestanol (Standard)	Reference Standards Interleukin Related	Others Metabolic Disease Inflammation/Immunology Cancer
Stigmastanol (Standard) is the analytical standard of Stigmastanol. This product is intended for research and analytical applications. Stigmastanol is a 6-amino derivative. Stigmastanol can be isolated from Hypericum riparium. Stigmastanol increases the secretion of *IL-2* and IL-10. Stigmastanol reduces the maximum mitochondrial respiration of cells. Stigmastanol has beneficial effects on the weakened immune function of asthma .

HY-161335

HPK1-IN-43	MAP4K Interleukin Related IFNAR	Cancer
HPK1-IN-43 (compound 9f) is a HPK1 kinase inhibitor with the IC₅₀ value of 0.32 nM. HPK1-IN-43 inhibits the phosphorylation of the downstream protein SLP-76 and enhances the secretion of interleukin-2 (IL-2) and interferon-γ (IFN-γ). HPK1-IN-43 can be used in cancer research .

HY-P991353

Sym-021	PD-1/PD-L1	Cancer
Sym-021 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. Sym-021 blocks the binding of PD-L1 and PD-L2 ligands, inducing the secretion of interferon IFN-γ and IL-2 and the proliferation of T cells. Sym-021 has anti-tumor activity in PDX mouse models .

HY-159902

KRN7000 analog 3	Interleukin Related	Inflammation/Immunology Cancer
KRN7000 analog 3 (Compound 14),α-GalCer (HY-102022) analogue, is a iNKT agonist. KRN7000 analog 3 induces higher levels of IL-2 cytokine secretion (49.2-62.6 ng/mL) than a-GalCer (44.1 ng/mL) in mNK1.2 cells. KRN7000 analog 3 is promising for research of antitumor agents and vaccine adjuvants .

HY-N6939R

Pseudolaric Acid B (Standard)	Reference Standards HBV Fungal Apoptosis Autophagy Ferroptosis HIF/HIF Prolyl-Hydroxylase Interleukin Related	Infection Cardiovascular Disease Inflammation/Immunology Cancer
Pseudolaric Acid B (Standard) is the analytical standard of Pseudolaric Acid B. This product is intended for research and analytical applications. Pseudolaric Acid B is an orally active diterpene acid. Pseudolaric Acid B has anti-fungal, anti-fertility, anti-angiogenesis and anticancer activity, and can induce tumor cell apoptosis and autophagy. In addition, Pseudolaric Acid B can inhibit the secretion of hepatitis B virus (HBV) and has immunosuppressive effect, selectively inhibiting the proliferation of T lymphocytes and the production of *IL-2* .

HY-172594

HPK1-IN-57	MAP4K Interleukin Related	Inflammation/Immunology Cancer
HPK1-IN-57 (Compound 10c) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC₅₀ value of 0.09 nM. HPK1-IN-57 inhibits the activity of HPK1 kinase, hindering the phosphorylation of the downstream adaptor protein SLP76 (IC₅₀ is 33.74 nM) and effectively stimulating the secretion of the T cell activation marker IL-2 (EC₅₀ is 84.24 nM). HPK1-IN-57 is promising for research of tumor immunotherapy .

HY-P5870

KTX-Sp2	Potassium Channel	Inflammation/Immunology
KTX-Sp2 is a potassium channel toxin. KTX-Sp2 effectively blocks three types of exogenous voltage-gated potassium channels: Kv1.1, Kv1.2 and Kv1.3. Ktx-Sp2 inhibits endogenous Kv1.3 and suppresses Ca ²⁺ signaling in Jurkat T cells. Ktx-Sp2 inhibits IL-2 secretion from activated Jurkat T cells .

HY-179111

HPK1-IN-64	MAP4K Interleukin Related	Cancer
HPK1-IN-64 is a potent, selective, and orally active HPK1 inhibitor with an IC₅₀ value of 1.9 nM. HPK1-IN-64 exhibits selectivity exceeding 100-fold, 80-fold, 300-fold, and 350-fold against off-target kinases such as GLK, MAP4K5, TBK1, and TNIK, respectively. HPK1-IN-64 inhibits SLP76 protein phosphorylation and *IL-2* secretion. HPK1-IN-64 may be used in cancer research, such as for colorectal cancer .

HY-175195

Adenosine receptor antagonist 6	Adenosine Receptor Interleukin Related IFNAR Cytochrome P450	Inflammation/Immunology Cancer
Adenosine receptor antagonist 6 is an orally active and selective A_2A adenosine receptor (A_2AAR) antagonist, with a K_i of 19.18 nM. Adenosine receptor antagonist 6 inhibits 5’-N-ethylcarboxamide adenosine (NECA) (HY-103173)-mediated cAMP production (IC₅₀ = 0.089 μM) and immunosuppression, while promoting *IL-2* and IFN-γ secretion. Adenosine receptor antagonist 6 abolishes the immunosuppressive effects of adenosine on T-cell activation and cytokine release. Adenosine receptor antagonist 6 inhibits tumor growth in a CT26/MC38 xenograft model. Adenosine receptor antagonist 6 can be used for the study of colon cancer .

HY-P990716

Sabestomig AZD7789	PD-1/PD-L1 Tim3	Inflammation/Immunology
Sabestomig (AZD7789) is a monovalent bispecific antibody targeting PD-1 and TIM-3. Sabestomig binds to PD-1 and an epitope in the TIM-3 IgV domain outside the phosphatidylserine-binding cleft, thereby precisely regulating immune responses. Sabestomig promotes IL-2 production, efferocytosis and cross-presentation of tumor antigens, and enhances the release of anti-tumor T cell cytokines, cytotoxicity, and secretion of IFN-γ. Sabestomig inhibits the growth of solid tumors, prolongs the duration of tumor suppression, and significantly enhances anti-tumor responses following anti-PD-1 therapy. Sabestomig has been used in studies related to non-small cell lung cancer and classical Hodgkin lymphoma .

HY-159892

PD-1/PD-L1-IN-54	PD-1/PD-L1 IFNAR Interleukin Related PI3K Akt	Cancer
PD-1/PD-L1-IN-54 (Compound 6) is a moderately affinic PD-1/PD-L1 inhibitor (K_D: PD-1, 55.8 μM; PD-L1, 46.4 μM; IC₅₀: 88.6 μM). PD-1/PD-L1-IN-54 inhibits PD-1/PD-L1 interactions and shows anticancer activity by activating CD8 ⁺ T cells, upregulating PD-1 expression, and increasing secretion of IFN-γ and *IL-2. PD-1/PD-L1-IN-54 inhibits cancer cell proliferation and promotes apoptosis. PD-1/PD-L1-IN-54 also regulates T cell immunity through the PI3K/Akt* pathway correlated with PD-1/PD-L1 .

HY-N0534R

Vitexin-2"-O-rhamnoside (Standard)	Reference Standards DNA/RNA Synthesis Apoptosis PI3K Akt Caspase SOD Interleukin Related	Cardiovascular Disease Inflammation/Immunology Cancer
Vitexin-2"-O-rhamnoside (Standard) is the analytical standard of Vitexin-2"-O-rhamnoside (HY-N0534). This product is intended for research and analytical applications. Vitexin-2"-O-rhamnoside is an orally active flavonoid glycoside. Vitexin-2"-O-rhamnoside inhibits Apoptosis, increases the phosphorylation levels of PI3K/Akt, inhibits caspase-3, SOD activity, and promotes cytokine (IL-2, IL-6, and IL-12) secretion. Vitexin-2"-O-rhamnoside strongly inhibits DNA synthesis in MCF-7 cells with an IC₅₀ of 17.5 μM. Vitexin-2"-O-rhamnoside enhances immune function and improves the absorption of active compounds. Vitexin-2"-O-rhamnoside has antioxidant activity. Vitexin-2"-O-rhamnoside is used in the study of cardiovascular disease and immune-related diseases .

HY-149201

VISTA-IN-1	VISTA Interleukin Related	Cancer
VISTA-IN-1 is an orally active VISTA inhibitor. VISTA-IN-1 inhibits the function of VISTA and promotes the secretion of *IL-2*. VISTA-IN-1 exerts inhibitory effects on mouse melanoma in vivo. VISTA-IN-1 is applicable to melanoma-related research .

HY-P991960

JS007	CTLA-4 Interleukin Related	Cancer
JS007 is a humanized IgG1 monoclonal antibody and also a CTLA-4 binder, with a K_d of 0.21 nM for CTLA-4. JS007 blocks the interaction between CTLA-4 and B7-1. JS007 activates T cells, promotes increased *IL-2* secretion, and inhibits tumor growth in CTLA-4 knock-in mouse syngeneic tumor models. JS007 is applicable to research related to cancer and advanced solid tumors.

HY-179617

Cbl-b-IN-30	E1/E2/E3 Enzyme Interleukin Related	Cancer
Cbl-b-IN-30 is an orally active Casitas B-lineage lymphoma-b (CBLB) inhibitor. Cbl-b-IN-30 specifically binds to CBLB and inhibits its E3 ubiquitin ligase activity with an IC₅₀ of 9.1 nM. Cbl-b-IN-30 can promote *IL-2* secretion (EC₅₀ = 187.5 nM) and enhance T cell activation. Cbl-b-IN-30 exerts antitumor activity and can induce immune memory. Cbl-b-IN-30 can be used for the research of colon cancer .

HY-179727

PROTAC HPK1 Degrader-7	PROTACs MAP4K Interleukin Related IFNAR	Inflammation/Immunology
PROTAC HPK1 Degrader-7 (compound D02) is a potent and selective PROTAC HPK1 degrader with an DC₅₀ of 3.07 nM. PROTAC HPK1 Degrader-7 exhibits selectivity over GLK. PROTAC HPK1 Degrader-7 induces HPK1 degradation in a CRBN- and proteasome-dependent manner. PROTAC HPK1 Degrader-7 inhibits SLP-76 phosphorylation, induces *IL-2* and IFN-γ secretion in human primary T cells. PROTAC HPK1 Degrader-7 can be used for immunology research .

HY-13743R

Roquinimex (Standard) Linomide (Standard); FCF89 (Standard); ABR212616 (Standard)	Reference Standards TNF Receptor Interleukin Related IFNAR	Inflammation/Immunology
Roquinimex (Standard) is the analytical standard of Roquinimex (HY-13743). Roquinimex (Linomide) is an orally active immunomodulator with antineoplastic, anti-inflammatory, and antiangiogenic activity. Roquinimex suppresses TH1 lymphocyte cytokines (IL-2, IFN-γ), promotes TH2 lymphocyte cytokines (IL-4, IL-10), increases NK cell, activated monocyte, and T cell activity. Roquinimex blocks macrophage TNF-α production and suppresses IL-1/IL-6 secretion. Roquinimex exhibits in vivo antitumour activity, suppresses rodent autoimmune disease signs, and ameliorates murine colitis and psoriasis. Roquinimex can be used for the research of leukemia, inflammatory bowel disease, multiple sclerosis, and psoriasis .

HY-182369

VA06	Toll-like Receptor (TLR) TNF Receptor Interleukin Related IFNAR Drug Derivative	Inflammation/Immunology
VA06 is a derivative of QS-21 (HY-101092A) that retains potent adjuvant activity while significantly reducing toxicity. VA06 self-assembles into flexible worm-like micelles with continuously elongated nanostructures and enhanced drug-loading encapsulation capacity. VA06 induces antigen-specific antibody production, enhances the secretion of TNF-α, IFN-γ and *IL-2* in CD4 ⁺ and CD8 ⁺ T cells, and promotes the expression of immune-related and antiviral-related genes in mature dendritic cells. VA06 does not require liposome formulation, which simplifies production and storage processes. VA06 can be used in the research of varicella-zoster virus infection and Mycobacterium tuberculosis infection .

HY-100712R

DPO-1 (Standard)	Potassium Channel Reference Standards Calcium Channel NOD-like Receptor (NLR) Interleukin Related	Cardiovascular Disease Inflammation/Immunology
DPO-1 (Standard) is the analytical standard of DPO-1 (HY-100712). This product is intended for research and analytical applications. DPO-1 is a potent Kv1.5 and Kv1.3 (EC50 = 3.1 μM) channels inhibitor with potential immunomodulatory and anti-inflammatory effects. DPO-1 reduces Kv1.3 current density, blunts Ca2+ influx in Ca2+-depleted Jurkat cells, and inhibits IL-2 secretion in activated Jurkat cells. DPO-1 inhibits Uric acid sodium (HY-B2130A) (MSU)-induced NLRP3 inflammasome activation by blocking Kv1.5-mediated K+ efflux. DPO-1 can be used for the study of immunologic disorders and atrial fibrillation .

Cat. No.	Product Name	Target	Research Area